Relation between DNA ploidy and the clinical behavior of phyllodes tumors

Abstract

We studied the DNA histograms obtained by flow cytometry from a series of six giant fibroadenomas and ten phyllodes tumors to determine if the analysis of DNA ploidy would help to predict clinical behavior. We were unable to document any relation between ploidy and histologic appearance, recurrence, metastasis, lesion size, or patient age. DNA aneuploid stem cell lines were seen in 75% of histologically benign phyllodes tumors, 50% of histologically malignant phyllodes tumors, and approximately 33% of giant fibroadenomas.

Proliferating activity in differential diagnosis of benign phyllodes tumor and cellular fibroadenomas: Is it helpful?

“…The tumor sizes of three FA patients were 6, 7 and 12 cm which were defined as giant fibroadenomas (4 cm and larger). 6 …”

Borderline and malignant phyllodes tumors display similar promoter methylation profiles

“…Several grading systems have been proposed consisting of either two or three subgroups [2][3][4]. Recently, the 2003 WHO classification of tumors proposed a classification of breast PTs in three categories (benign, borderline, and malignant).…”

Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study

“…They are composed of stromal and epithelial elements analogous to fibroadenoma, although the stroma generally is more cellular and may outgrow the epithelium. Clinically, most of these tumors tend to behave in a benign fashion, but, unlike fibroadenomas, they can recur locally and can undergo sarcomatous transformation [4,5]. Histologically, PTs are classified as benign, borderline, or malignant on the basis of stromal cellularity, nuclear atypia, mitotic activity, stromal distribution, and margin appearance (infiltrating or pushing) (see Fig.…”